NuCana (NASDAQ:NCNA) Stock Price Up 2.9% – Should You Buy?

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) rose 2.9% during trading on Thursday . The company traded as high as $1.44 and last traded at $1.43. Approximately 49,000 shares changed hands during trading, a decline of 50% from the average daily volume of 97,747 shares. The stock had previously closed at $1.39.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

NuCana Trading Down 2.1%

The company has a 50-day simple moving average of $1.40 and a 200 day simple moving average of $1.77. The company has a market cap of $5.83 million, a P/E ratio of -0.37 and a beta of 2.23.

NuCana (NASDAQ:NCNA) last released its earnings results on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($2.65) by $1.66.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.